Application of fish maw mucopolysaccharide in the preparation of liver injury drugs

Through the application of fish bladder mucopolysaccharide, the liver damage caused by arsenic exposure is solved, which significantly improves liver cell damage and necrosis, restores the antioxidant activity of liver tissue, activates the endogenous antioxidant system, and provides liver protection for the early stage of arsenic exposure. and effective ways to relieve liver damage.

CN118542882BActive Publication Date: 2024-12-03GUANGDONG OCEAN UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411008139.0
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-12-03
Estimated Expiration
2044-07-26

AI Technical Summary

Technical Problem

Drugs that cause liver damage due to arsenic exposure lack effective protective measures, and the prior art is difficult to provide significant liver protection and alleviate liver damage in the early stage of exposure.

Method used

Using fish bladder mucopolysaccharide as the main component, by gavage of 50-200mg/kg of fish bladder mucopolysaccharide, hepatic sinusoidal congestion, liver cell hollowing, inflammatory infiltration and other pathological damages, and regulate the body's oxidative stress and toxicity-related gene expression , slow down oxidative damage to liver tissue.

Benefits of technology

Significantly improve liver cell damage and necrosis caused by arsenic exposure, restore antioxidant activity of liver tissue, increase the relative expression of Nrf2 protein, activate the endogenous antioxidant system, slow down the effect of arsenic toxicity, and improve oxidative damage of liver tissue.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118542882B_ABST
    Figure CN118542882B_ABST
Patent Text Reader

Abstract

The present invention belongs to the field of biomedicine technology, and discloses the use of fish bladder mucopolysaccharide in the preparation of liver injury drugs. Fish bladder mucopolysaccharide can improve arsenic-induced congestion of hepatic sinusoids and central veins, cytoplasmic vacuolation of liver cells, inflammatory infiltration and other pathological damages, can improve arsenic-induced liver cell damage and necrosis, liver tissue oxidative imbalance, and can also significantly upregulate the relative expression of antioxidant-related genes in liver tissue, downregulate the relative expression of toxin-related genes, and alleviate arsenic-induced liver damage. The fish bladder mucopolysaccharide of the present invention has good application prospects in alleviating liver damage caused by arsenic exposure.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine and relates to the application of fish maw mucopolysaccharide in the preparation of liver injury medicine. Background Art

[0002] Fish maw, also known as fish glue, is a tonic that is both a medicine and a food. It is rich in a variety of functional active substances, and its main components include collagen, mucopolysaccharides, vitamins, and trace elements such as calcium, zinc, potassium, and selenium. Fish maw mucopolysaccharides are a type of extracellular biopolymer secreted by cells. They are the sugar chain part of the proteoglycan molecules in animals. They have the functions of regulating inorganic substances and water in extracellular fluid, promoting bone formation, promoting wound healing, preventing infection, lubricating cartilage, preventing thrombosis, purifying blood, and maintaining corneal transparency. The existing patent CN117018020A discloses that fish maw glycosaminoglycans can slow down the occurrence of intestinal oxidative stress and inflammation, and have good application prospects in the preparation of intestinal injury drugs.

[0003] Arsenic is an environmental pollutant with carcinogenic risk that is widely present in the earth's crust, soil and air. Due to the high accumulation capacity of aquatic organisms for arsenic, in recent years, exposure to arsenic has become a common way for arsenic to enter the body. Arsenic exposure can cause damage to multiple organs such as the liver, kidneys, intestines, nervous system and reproductive system. Among them, the liver is the most important metabolic organ of arsenic, and related research on arsenic-induced liver damage has received relatively wide attention. Studies have shown that arsenic exposure can cause liver damage such as liver fibrosis, non-alcoholic fatty liver disease and liver cancer, and the causes are related to arsenic-induced oxidative stress, ferroptosis and autophagy.

[0004] Since arsenic-induced liver damage is often an accumulation process, there is usually no obvious phenotype in the early stage of exposure, and acute damage begins to appear after accumulation to a certain extent. Therefore, it is very important to provide a drug that has a liver-protective effect in the early stage of arsenic exposure and can alleviate liver damage caused by arsenic exposure. Summary of the invention

[0005] In order to solve the above technical problems, the present invention provides the use of fish bladder mucopolysaccharide in the preparation of liver injury drugs. Fish bladder mucopolysaccharide can improve pathological damage such as liver sinusoidal congestion, liver cell cavitation, inflammatory infiltration, etc., can improve liver cell damage and necrosis, slow down the oxidative damage of liver tissue and regulate the expression of genes related to slowing down toxicity. The present invention promotes the utilization of fish bladder resources and provides a method for alleviating liver damage caused by arsenic exposure.

[0006] To achieve the technical purpose of the present invention, on the one hand, the present invention provides the use of fish maw mucopolysaccharide in the preparation of liver injury drugs, wherein the liver injury is arsenic-induced liver injury, and the effective ingredient dosage of fish maw mucopolysaccharide is 50-200 mg / kg.

[0007] Furthermore, the fish bladder mucopolysaccharide provided by the present invention can alleviate the liver pathological damage induced by arsenic, including: congestion of the hepatic sinusoids and central veins, small focal infiltration of lymphocytes, and cytoplasmic vacuolation of liver cells. The present invention observed the results of HE staining of mouse liver sections and found that in the arsenic exposure model group, it can be clearly seen that the hepatic sinusoids and central veins were congested, accompanied by small focal infiltration of lymphocytes and cytoplasmic vacuoles in multiple liver cells; after continuous gavage of 50-200 mg / kg of fish bladder mucopolysaccharide for 38 days, the congestion of the hepatic sinusoids, congestion of the central veins and small focal infiltration of lymphocytes were significantly improved, the morphological structure of liver cells was intact, and there was almost no cytoplasmic vacuolation.

[0008] Furthermore, the fish bladder mucopolysaccharide provided by the present invention can alleviate hepatocyte damage and necrosis induced by arsenic, specifically including: increased hepatocyte ALT activity and increased hepatocyte AST activity. The present invention determined the liver cell damage index of mice and found that arsenic exposure can cause the hepatocyte ALT activity level to increase by 128.49% and the hepatocyte AST activity level to increase by 63.58%, causing severe hepatocyte necrosis; after continuous gavage of 50-200 mg / kg of fish bladder mucopolysaccharide for 38 days, the ALT and AST levels in the mouse serum returned to the level of the control group, indicating that fish bladder mucopolysaccharide can effectively improve arsenic-induced hepatocyte damage and necrosis.

[0009] Furthermore, the fish bladder mucopolysaccharide provided by the present invention can alleviate the oxidative imbalance of liver tissue induced by arsenic, specifically including: the T-SOD activity and GSH content in the liver tissue are reduced. The present invention found that arsenic exposure can cause a significant decrease in the T-SOD activity and GSH content in the liver tissue representing antioxidant activity by measuring the oxidation index of mouse liver tissue, and the decrease levels are 18.29% and 64.40%, respectively, which can cause oxidative imbalance in liver tissue; after continuous gavage of 50~200mg / kg of fish bladder mucopolysaccharide for 38 days, the T-SOD activity and GSH content in the liver tissue of mice were significantly improved, indicating that fish bladder mucopolysaccharide can effectively improve oxidative damage to liver tissue.

[0010] Furthermore, the fish maw mucopolysaccharide provided by the present invention can significantly upregulate the relative expression of antioxidant-related genes and downregulate the relative expression of detoxification-related genes, and can effectively improve oxidative damage in liver tissue. Antioxidant-related genes include Nrf2 gene, SOD-1 gene and GPX-4 gene, and detoxification-related genes include MT-1 gene.

[0011] Furthermore, the fish bladder mucopolysaccharide provided by the present invention can increase the relative expression of Nrf2 protein in the nuclear protein of liver tissue. The fish bladder mucopolysaccharide significantly promotes the nuclear entry of Nrf2, activates the expression of the endogenous antioxidant system, and can effectively play the role of the body in alleviating arsenic toxicity.

[0012] Compared with the prior art, the technical solution provided by the present invention has at least the following beneficial effects or advantages:

[0013] The results of HE staining of mouse liver sections observed in the present invention showed that in the arsenic exposure model group, congestion of the hepatic sinusoids and central veins, accompanied by small focal infiltration of lymphocytes and cytoplasmic vacuoles in multiple hepatocytes were clearly observed; after continuous gavage of 50-200 mg / kg of fish maw mucopolysaccharide for 38 days, congestion of the hepatic sinusoids, congestion of the central veins and small focal infiltration of lymphocytes were significantly improved, the morphological structure of hepatocytes was intact, and there was almost no cytoplasmic vacuoles.

[0014] The present invention determined the liver cell damage indicators of mice and found that arsenic exposure would cause the ALT activity level of liver cells to increase by 128.49% and the AST activity level of liver cells to increase by 63.58%, resulting in severe liver cell necrosis; after continuous gavage of 50-200 mg / kg of fish bladder mucopolysaccharide for 38 days, the ALT and AST levels in the mouse serum returned to the enzyme levels of the control group, indicating that fish bladder mucopolysaccharide can effectively improve arsenic-induced liver cell damage and necrosis.

[0015] By measuring the oxidation indicators of mouse liver tissue, the present invention found that arsenic exposure would cause a significant decrease in T-SOD activity and GSH content in liver tissue, which represent antioxidant activity, by 18.29% and 64.40%, respectively, which would cause oxidative imbalance in liver tissue; after continuous gavage of 50-200 mg / kg of fish bladder mucopolysaccharide for 38 days, the T-SOD activity and GSH content in the liver tissue of mice were significantly increased, indicating that fish bladder mucopolysaccharide can effectively improve oxidative damage to liver tissue.

[0016] The present invention determines the relative expression of antioxidant genes and detoxification genes in mouse liver tissue and finds that fish bladder mucopolysaccharide can significantly increase the relative expression of antioxidant-related genes and decrease the relative expression of genes representing detoxification ability, which can effectively improve liver tissue oxidative damage. The fish bladder mucopolysaccharide of the present invention significantly promotes the nuclear entry of Nrf2, activates the expression of the endogenous antioxidant system, and can effectively play the role of the body in mitigating arsenic toxicity. BRIEF DESCRIPTION OF THE DRAWINGS

[0017] Figure 1 HE staining results of liver sections of mice in different experimental groups.

[0018] Figure 2 The results of liver cell damage determination in mice of different experimental groups. Figure 2 A in the figure is the determination result of ALT activity of liver cells in mice in different experimental groups; Figure 2 B in the figure is the measurement result of AST activity of liver cells in mice in different experimental groups.

[0019] Figure 3These are the results of measuring oxidation indices in liver tissue of mice in different experimental groups. Figure 3 A in the figure is the result of determination of T-SOD activity in liver tissue of mice in different experimental groups; Figure 3 B in the figure is the determination result of GSH content in liver tissue of mice in different experimental groups.

[0020] Figure 4 These are the results of determining the relative expression levels of toxicity-alleviating genes in the liver tissues of mice in different experimental groups. Figure 4 A in the figure is the determination result of the relative expression of Nrf2 gene in the liver tissue of mice in different experimental groups; Figure 4 B in the figure is the result of determination of relative expression of SOD-1 gene in liver tissue of mice in different experimental groups; Figure 4 C in the figure is the determination result of the relative expression of GPX-4 gene in the liver tissue of mice in different experimental groups; Figure 4 D in the figure is the determination result of the relative expression level of MT-1 gene in the liver tissue of mice in different experimental groups.

[0021] Figure 5 The results show the relative expression of Nrf2 protein in nuclear protein of liver tissue of mice in different experimental groups. Figure 5 A in the figure is the electrophoretic band diagram of the relative expression of Nrf2 protein in the nuclear protein of liver tissue of mice in different experimental groups; Figure 5 B is the statistical result of the relative expression of Nrf2 protein in the nuclear protein of liver tissue of mice in different experimental groups. DETAILED DESCRIPTION

[0022] The technical scheme of the present invention is now described in conjunction with the embodiments, but the present invention is not limited to the following embodiments. The experimental methods and detection methods described in the following embodiments are conventional methods unless otherwise specified; the reagents and materials described are all commercially available unless otherwise specified.

[0023] Example 1

[0024] This example provides an animal experiment on the improvement of fish bladder mucopolysaccharide on arsenic-induced liver damage in mice. The preparation method of fish bladder mucopolysaccharide is the same as Example 1 in patent CN112107590B. The fish bladder mucopolysaccharide is a chondroitin sulfate A analogue containing a →4GlcUAβ1→3GalNAc(4S)β1→ main chain.

[0025] 1. Establish a test model

[0026] Sixty male SPF-level C57BL / 6J mice (18±2g, 7 weeks old) were randomly divided into 5 groups (control group, model group, low-dose group, medium-dose group and high-dose group), with 12 mice in each group. The experimental group was divided into three groups according to the oral dose of fish bladder mucopolysaccharide, including low-dose group, medium-dose group and high-dose group. The oral dose of the low-dose group was 50mg / kg, the oral dose of the medium-dose group was 100mg / kg, and the oral dose of the high-dose group was 200mg / kg. The experimental group was gavaged with fish bladder mucopolysaccharide solution in the morning and 5mg / kg sodium arsenite solution in the afternoon; the model group was gavaged with 0.1mL / 10g normal saline in the morning and 5mg / kg sodium arsenite solution in the afternoon; the control group was gavaged with 0.1mL / 10g normal saline in the morning and afternoon. After each group of mice were gavaged every day, they were allowed to eat freely. The experimental groups (control group, model group, low-dose group, medium-dose group and high-dose group) were given continuous gavage for 38 days. After the last gavage, the mice were killed and the eye serum and liver tissue were collected.

[0027] 2. Observation of mouse liver pathology

[0028] The same part of the largest lobe of the mouse liver was fixed in 4% paraformaldehyde, embedded in paraffin, sectioned, and stained with H&E, and the tissue morphology was observed under an optical microscope (×200). Figure 1 shown.

[0029] Depend on Figure 1 It can be seen that compared with the control group, the arsenic exposure model group can clearly see congestion in the hepatic sinusoids and central veins (circles), accompanied by small focal infiltration of lymphocytes (rectangles) and cytoplasmic vacuoles in multiple liver cells (arrows). After the action of fish bladder mucopolysaccharides, the liver of mice has improved to varying degrees, as shown by: the morphological structure of liver cells is intact, and there is almost no cytoplasmic vacuoles; the congestion and inflammatory infiltration of the central veins have been significantly improved.

[0030] 3. Determination of basic indicators of liver damage in mice

[0031] The levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in mouse serum (liver cell damage assay) and the activity of total superoxide dismutase (T-SOD) and glutathione (GSH) content in liver tissue (liver tissue oxidation assay) were determined according to the instructions of the detection kit (all purchased from Nanjing Jiancheng Bioengineering Institute). The activity levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in mouse serum were as follows: Figure 2 As shown in Figure 2, the total superoxide dismutase (T-SOD) activity and glutathione (GSH) content in mouse liver tissue were Figure 3 shown.

[0032] Depend on Figure 2It can be seen that compared with the control group, the ALT and AST activity levels in the serum of the arsenic exposure model group, which represent liver cell damage and necrosis, were significantly increased, with the improvement effects of 128.49% and 63.58%, respectively, indicating that arsenic exposure caused severe liver cell necrosis. The release of the two enzymes can be significantly reduced after the action of fish bladder mucopolysaccharide at each dose, and the ALT and AST levels in the mouse serum returned to the enzyme levels of the control group, indicating that fish bladder mucopolysaccharide can effectively improve arsenic-induced liver cell damage and necrosis. In terms of ALT activity level, the medium-dose group had the best effect, and the ALT activity was significantly reduced compared with the model group, by 46.97%. In terms of AST activity level, the high-dose group had the best effect, and the AST activity was reduced by 55.53% compared with the model group.

[0033] Depend on Figure 3 It can be seen that compared with the control group, the T-SOD activity and GSH content representing antioxidant activity in the liver tissue of the arsenic exposure model group were significantly reduced, with a decrease of 18.29% and 64.40%, respectively, indicating that arsenic exposure can cause oxidative imbalance in liver tissue. After the action of fish bladder mucopolysaccharide, the T-SOD activity and GSH content were significantly improved, indicating that fish bladder mucopolysaccharide can effectively improve oxidative damage in liver tissue. Among them, the T-SOD activity of the liver tissue of mice in the high-dose group was slightly higher than that of the control group, indicating that fish bladder mucopolysaccharide has good antioxidant activity; in terms of GSH content level, the medium-dose group had the best effect, and the GSH content of the mouse liver tissue was significantly higher than that of the control group, and was 4.39 times that of the model group.

[0034] 4. Determination of relative expression of liver toxicity alleviation genes in mice

[0035] RNA was extracted from mouse liver tissue using an RNA extraction kit, and then cDNA was obtained by reverse transcription. RNA fluorescence quantitative reagent was then added, and the relative expression levels of Nrf2 gene, SOD-1 gene, GPX-4 gene and MT-1 gene were determined by RT-qPCR. The internal reference gene was GADPH, and the calculation formula was 2 –ΔΔCt . The Nrf2 gene is a gene related to antioxidants, as it regulates the expression of a series of antioxidant enzymes, maintains the intracellular redox balance, and protects cells from oxidative stress damage. Cu / Zn superoxide dismutase 1 (SOD-1) is a gene related to antioxidants. The GPX-4 gene is a gene related to antioxidants in mouse liver tissue. Metallothionein (MT) is an endogenous cell protector that can fight liver toxicity by scavenging free radicals and anti-oxidation. The MT-1 gene is a gene related to detoxification ability in mouse liver tissue. The relative expression levels of the Nrf2 gene, SOD-1 gene, GPX-4 gene, and MT-1 gene in mouse liver tissue are shown in Figure 2. Figure 4 shown.

[0036] Depend on Figure 4 It can be seen that compared with the control group, the Nrf2 gene, SOD-1 gene and GPX-4 gene representing antioxidant capacity in the liver tissue of the arsenic exposure model group showed a downward trend, among which the Nrf2 gene and GPX-4 gene decreased significantly; the relative expression of the MT-1 gene representing detoxification capacity increased significantly. The relative expression of the Nrf2 gene decreased by 36.01%, the SOD-1 gene decreased by 14.83%, the GPX-4 gene decreased by 59.42%, and the MT-1 gene increased by 9.60 times, indicating that arsenic exposure can cause severe oxidative damage to the mouse liver. After the action of fish bladder mucopolysaccharide, the relative expression of the antioxidant Nrf2 gene, SOD-1 gene and GPX-4 gene was significantly upregulated, and the relative expression of the MT-1 gene was downregulated. Among them, the high-dose group had the best improvement effect after the fish bladder mucopolysaccharide was used. Compared with the model group, the effects of upregulating the relative expression of Nrf2 gene, SOD-1 gene and GPX-4 gene were 100.39%, 99.68% and 211.44% respectively, which can significantly upregulate genes representing antioxidant capacity; the high-dose group can also significantly downregulate the relative expression of MT-1 gene, which was downregulated by 46.92% compared with the model group. The results show that fish bladder mucopolysaccharide can effectively improve oxidative damage in liver tissue.

[0037] 5. Determination of the relative expression of Nrf2 protein in the nuclear protein of mouse liver tissue

[0038] Nrf2 protein binds to the antioxidant response element in the promoter region of cell protection genes and is a transcription factor associated with oxidative stress response. Nuclear proteins in liver tissue were extracted according to the relevant steps of the nuclear protein extraction kit (purchased from Shanghai Biyuntian Biotechnology Co., Ltd.), and then the concentration of each sample was determined using a protein quantification kit (purchased from Shanghai Biyuntian Biotechnology Co., Ltd.). After adjusting them to be consistent, 5×SDS-PAGE protein loading buffer was added, and then the protein was denatured at 100°C for 10 minutes. The protein was separated by SDS-PAGE electrophoresis, and then transferred to a PVDF membrane. After blocking at room temperature for 1 hour, it was incubated with the primary antibodies LaminB1 and Nrf2 (antibody dilution was 1:1000) at 4°C overnight, and then incubated with the corresponding secondary antibodies (dilution was 1:3000) at room temperature for 1 hour. It can be immersed in the ultrasensitive ELC working solution and imaged using a chemiluminescence system. The obtained protein band diagram was analyzed in grayscale using Image J software, and the final data was presented as the ratio of the grayscale of the target protein / the grayscale of the internal reference LaminB1. The results of the determination of the relative expression of Nrf2 protein in the nuclear protein of mouse liver tissue are as follows Figure 5 shown.

[0039] Depend on Figure 5It can be seen that compared with the control group, the level of Nrf2 in the nucleus of liver tissue in the arsenic exposure model group increased, indicating that arsenic induced oxidative stress. After the action of fish bladder mucopolysaccharide, each dose group significantly promoted the entry of Nrf2 into the nucleus and activated the expression of the endogenous antioxidant system. Among them, the degree of activation was the highest under the action of the medium dose. This result shows that fish bladder mucopolysaccharide is an Nrf2 activator, which can effectively activate the body's antioxidant system and play a role in alleviating arsenic toxicity.

[0040] As described above, the basic principle, main features and advantages of the present invention are well described. The above embodiments and descriptions are only descriptions of the preferred embodiments of the present invention, and the present invention is not limited by the above embodiments. Without departing from the spirit and scope of the present invention, various changes and improvements made by ordinary technicians in this field to the technical solution of the present invention should fall within the protection scope determined by the present invention.

Claims

1. Application of fish maw mucopolysaccharide in the preparation of liver injury drugs, It is characterized in that The liver damage is arsenic-induced liver damage; The effective ingredient dosage of the fish maw mucopolysaccharide is 50-200 mg / kg; The fish swim bladder mucopolysaccharide alleviates liver pathological damage induced by arsenic; The arsenic-induced liver pathological damage includes: congestion of the hepatic sinusoids and central veins, small focal infiltration of lymphocytes, and cytoplasmic vacuolation of liver cells; The swim bladder mucopolysaccharide reduces the relative expression of detoxification-related genes, and the detoxification-related genes include the MT-1 gene.

2. The use of the fish maw mucopolysaccharide according to claim 1 in the preparation of a liver injury drug, It is characterized in that The fish swim bladder mucopolysaccharide alleviates liver cell damage and necrosis induced by arsenic; The hepatocyte damage and necrosis induced by arsenic include: increased hepatocyte ALT activity and increased hepatocyte AST activity.

3. Use of the fish maw mucopolysaccharide according to claim 1 in preparing a liver injury drug, It is characterized in that The fish swim bladder mucopolysaccharide alleviates the oxidative imbalance of liver tissue induced by arsenic; The arsenic-induced liver tissue oxidation imbalance includes: a decrease in T-SOD activity and a decrease in GSH content in the liver tissue.

4. Use of the fish maw mucopolysaccharide according to claim 1 in preparing a liver injury drug, It is characterized in that The fish swim bladder mucopolysaccharide upregulates the relative expression of antioxidant-related genes in liver tissue; The antioxidant related genes include Nrf2 gene, SOD-1 gene and GPX-4 gene.

5. Use of the fish maw mucopolysaccharide according to claim 1 in preparing a liver injury drug, It is characterized in that The fish swim bladder mucopolysaccharide increases the relative expression of Nrf2 protein in the nuclear protein of liver tissue.